Wellington Management Group LLP boosted its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 2.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,656,264 shares of the company's stock after acquiring an additional 46,267 shares during the quarter. Wellington Management Group LLP owned about 3.95% of Artivion worth $44,090,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of AORT. The Manufacturers Life Insurance Company raised its holdings in shares of Artivion by 3.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company's stock worth $392,000 after purchasing an additional 481 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Artivion by 3.1% in the second quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company's stock valued at $510,000 after buying an additional 600 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Artivion by 6.6% during the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock valued at $280,000 after acquiring an additional 653 shares during the last quarter. Quarry LP boosted its stake in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after acquiring an additional 820 shares in the last quarter. Finally, nVerses Capital LLC acquired a new position in shares of Artivion in the 2nd quarter worth $28,000. 86.37% of the stock is owned by institutional investors and hedge funds.
NYSE AORT opened at $29.92 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -1,496.00 and a beta of 1.75. The company has a 50 day simple moving average of $27.58 and a 200-day simple moving average of $26.14. Artivion, Inc. has a 52-week low of $16.48 and a 52-week high of $30.45.
AORT has been the subject of a number of recent analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday. Oppenheimer raised their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. Needham & Company LLC restated a "buy" rating and set a $34.00 price target on shares of Artivion in a report on Monday. Finally, Stifel Nicolaus raised their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $31.80.
Read Our Latest Stock Analysis on AORT
In related news, CAO Amy Horton sold 4,329 shares of the business's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the completion of the sale, the chief accounting officer now owns 135,660 shares of the company's stock, valued at approximately $4,023,675.60. The trade was a 3.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Andrew M. Green sold 7,618 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now directly owns 33,503 shares in the company, valued at approximately $1,005,090. The trade was a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,377 shares of company stock worth $682,356 in the last quarter. 8.10% of the stock is currently owned by corporate insiders.
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.